Founder, CEO, GSBR Research

Garvit Bhandari

Founder, CEO

Leading Provider of Equity and Investment Research

GSBR Research

We are an independent equity research provider focused on covering global markets. The aim of the research is to provide an unbiased view of the fundamentals of the company.

Thematic (Sector/Industry)

<ul>
<li>US public EV charging stations reached 84,171 as of September 30, 2026 (up 5.0% versus end-FY25). Total EVSE ports hit 263,947, up 9.0% from end-2025 and 1.7% month-over-month.</li>
<li>Active DC Fast ports rose 2.7% month-on-month to 77,269, a fourth straight monthly gain; Tesla holds 50.0% of US DC Fast ports, ChargePoint 32.3% of all ports.</li>
<li>NREL sees a need for 1.0 million Level 2 chargers and 182,000 DC Fast points by 2030, at current growth rates, the US is likely to fall short.</li>
</ul>


US public EV charging stations reached 84,171 as of September 30, 2026 (up 5.0% versus end-FY25). Total EVSE ports hit 263,947, up 9.0% from end-2025 and 1.7% month-over-month.
Active DC Fast ports rose 2.7% month-on-month to 77,269, a fourth straight monthly gain; Tesla holds 50.0% of US DC Fast ports, ChargePoint 32.3% of all ports.
NREL sees a need for 1.0 million Level 2 chargers and 182,000 DC Fast points by 2030, at current growth rates, the US is likely to fall short.


US EV Charging Infrastructure September 2026: Both Stations and Ports Advance as DC Fast Accelerates

Smartkarma AI Synthetic Expert Call Transcripts, Smartkarma

αSK SmartScripts

Smartkarma AI Synthetic Expert Call Transcripts

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul><li>Ribupatide (KAI-9531) is positioned for high-BMI weight loss, but global market entry depends on mid-2028 KaiNETIC Phase 3 data: Kailera completed enrollment for its three pivotal Phase 3 trials in late September 2026, creating a high-burn R&amp;D period with key efficacy and safety readouts nearly two years away.</li><li>A $917 million balance sheet provides a cash runway through pivotal readouts: Strengthened by an upsized $625 million IPO in April 2026, Kailera's capital reserves protect it from near-term refinancing risks while funding the execution of its multi-asset GLP-1 pipeline.</li><li>Oral small-molecule KAI-7535 validated via Chinese Phase 3 data, but GI tolerability remains a key hurdle: While partner Hengrui demonstrated 10.9% weight loss at 44 weeks in China's HARBOR-1 trial, gastrointestinal adverse event rates require careful titration strategies to compete against established oral agents like Eli Lilly's orforglipron.</li></ul><div style="color: #475569; background: #eee; border-radius: 16px; padding: 14px; margin: 14px 0; font-size: 12px; line-height: 16px;">Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.</div>

Ribupatide (KAI-9531) is positioned for high-BMI weight loss, but global market entry depends on mid-2028 KaiNETIC Phase 3 data: Kailera completed enrollment for its three pivotal Phase 3 trials in late September 2026, creating a high-burn R&amp;D period with key efficacy and safety readouts nearly two years away.A $917 million balance sheet provides a cash runway through pivotal readouts: Strengthened by an upsized $625 million IPO in April 2026, Kailera's capital reserves protect it from near-term refinancing risks while funding the execution of its multi-asset GLP-1 pipeline.Oral small-molecule KAI-7535 validated via Chinese Phase 3 data, but GI tolerability remains a key hurdle: While partner Hengrui demonstrated 10.9% weight loss at 44 weeks in China's HARBOR-1 trial, gastrointestinal adverse event rates require careful titration strategies to compete against established oral agents like Eli Lilly's orforglipron.Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.

Kailera Therapeutics (KLRA US): Synthetic Expert Call Transcript (15 Oct 2026)

Semiconductor & Technology Specialist, Ingenuity

William Keating

Semiconductor & Technology Specialist

Ingenuity

Our focus is exclusively on in-depth research & consulting in the broader semiconductor industry. We focus on the key players, namely Intel, Micron, Qualcomm, Apple, Samsung, NVIDIA, AMD, TSMC & Global Foundries - as well as some of the lesser known, but nonetheless critical, companies such as ASML (for EUV), Mellanox, Cavium, Xilinx etc. We specialise in their products, roadmaps, process technologies, competitive advantages & threats etc. We also help our clients understand the implications of new and emerging technologies, e.g. 3D X-Point, 3D NAND, Carbon Nanotubes, Autonomous Driving, Graphene, Silicon Photonics, Wafer-Level Optics, Artificial Intelligence, FPGA, GPU, ASIC etc. 

Semiconductor Analysis & Research

Meta Platforms Inc. operates as a social technology company. The Company builds applications and technologies that help people connect, find communities, and grow businesses. meta Platform is also involved in advertisements, augmented and virtual reality.

<ul>
<li>Susan pulled me aside many times and was, you know, I just want to tell you, if this doesn’t work, you know, this is going to be really, really bad</li>
<li>We needed leadership in the company to be much more AI-pilled and much more sort of like forward-leaning and front-leaning on like how quickly the technology's moving,</li>
<li>You know, we're going to write this check for like, I don't know, like $100 billion, $200 billion. I'm like, Alex, are you sure this is going to work? </li>
</ul>


Susan pulled me aside many times and was, you know, I just want to tell you, if this doesn’t work, you know, this is going to be really, really bad
We needed leadership in the company to be much more AI-pilled and much more sort of like forward-leaning and front-leaning on like how quickly the technology's moving,
You know, we're going to write this check for like, I don't know, like $100 billion, $200 billion. I'm like, Alex, are you sure this is going to work? 


Zuckerberg & Wang Wax Lyrical Over Cheeky Pints With Stripe’s Collison

Smartkarma AI IPO Databooks, Smartkarma

αSK IPO Databooks

Smartkarma AI IPO Databooks

Equity Capital Markets

<ul><li><a href="https://smartkarma.com/entities/arxis-inc" target="_blank">Arxis</a>, Inc. is a leading designer and manufacturer of proprietary, mission-critical electronic and mechanical components engineered for cutting-edge performance in extreme environments.</li><li>The company acquired 37 companies since 2019 and operates 78 manufacturing facilities globally, reporting $959,586 thousand in revenue for six months ended June 30, 2026.</li><li><a href="https://smartkarma.com/entities/arxis-inc" target="_blank">Arxis</a> reported a net income of $48,400 for six months ended June 30, 2026, but also a net loss of $(4,909) for the three months ended June 30, 2026.</li></ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Arxis, Inc. is a leading designer and manufacturer of proprietary, mission-critical electronic and mechanical components engineered for cutting-edge performance in extreme environments.The company acquired 37 companies since 2019 and operates 78 manufacturing facilities globally, reporting $959,586 thousand in revenue for six months ended June 30, 2026.Arxis reported a net income of $48,400 for six months ended June 30, 2026, but also a net loss of $(4,909) for the three months ended June 30, 2026.This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Alternative Ballistics / Equity Capital Markets

Alternative Ballistics Corporation is a public safety technology company focused on developing and commercializing patented less-lethal solutions. Its flagship product, The Alternative®, is a bullet-capture system that attaches to a standard service firearm, enabling officers to deploy a less-lethal impact round while maintaining immediate access to lethal force.

<ul><li><a href="https://smartkarma.com/entities/alternative-ballistics" target="_blank">Alternative Ballistics</a> Corporation is a public safety technology company developing patented less-lethal solutions. Its flagship product, The Alternative®, is a bullet-capture system for standard service firearms.</li><li>The company holds 7 U.S. and 7 international patents for its less-lethal solutions, distributed globally via 28 partners across 48 countries.</li><li>The company reported a net loss of $(3,433,591) for six months ended June 30, 2026, with an audit firm expressing substantial doubt about its going concern.</li></ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Alternative Ballistics Corporation is a public safety technology company developing patented less-lethal solutions. Its flagship product, The Alternative®, is a bullet-capture system for standard service firearms.The company holds 7 U.S. and 7 international patents for its less-lethal solutions, distributed globally via 28 partners across 48 countries.The company reported a net loss of $(3,433,591) for six months ended June 30, 2026, with an audit firm expressing substantial doubt about its going concern.This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

IPO Databook: Alternative Ballistics (ALBC US) - Oct 2026